Verona Pharma (Verona Pharma) Common Stock : $42.77 Mil (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Verona Pharma Common Stock?

Verona Pharma's quarterly common stock increased from Sep. 2023 ($41.75 Mil) to Dec. 2023 ($42.77 Mil) but then stayed the same from Dec. 2023 ($42.77 Mil) to Mar. 2024 ($42.77 Mil).

Verona Pharma's annual common stock increased from Dec. 2021 ($31.86 Mil) to Dec. 2022 ($40.53 Mil) and increased from Dec. 2022 ($40.53 Mil) to Dec. 2023 ($42.77 Mil).

Verona Pharma Common Stock Historical Data

The historical data trend for Verona Pharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verona Pharma Common Stock Chart

Verona Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

7.27

31.79

31.86

40.53

42.77

Verona Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															41.75	41.75	41.75	42.77	42.77

Verona Pharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Verona Pharma (Verona Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (GREY:VNAPF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

VRNA:USA I9SA:Germany

Address

3 More London Riverside, London, GBR, SE1 2RE

Website

https://www.veronapharma.com

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. The company is engaged in pharmaceutical development.